Description: Lamifiban TFA (Ro-44-9883 trifluoroacetate; Ro 44-9883) is a novel and potent platelet fibrinogen receptor (GPIIb/IIIa) antagonist and a platelet aggregation inhibitor. Lamifiban prevents platelet loss during experimental cardiopulmonary bypass. Lamifiban inhibits platelet aggregation and thrombus formation by preventing the binding of fibrinogen to platelets.